Fentanyl produces a specific EEG signature distinct from other anesthetic drugs, which could make it possible to monitor its effects to enable safer, more precise, and personalized opioid administration.
- A Mass General-led team of public health modelers and substance use experts has developed a dynamic model based on national data from 1999 to 2020 that tracks the evolution of the opioid crisis for public policy analysis and development
- The tool, known as SOURCE, factors in the interconnecting stages of opioid use, from initiation to overdose to recovery, and how the transitions between stages shift over time
- SOURCE projects that deaths from opioid overdose will increase over the next few years before declining as opioid use disorder decreases
BOSTON – A data-driven simulation model designed to help policymakers to better understand and address the nation’s rampant opioid crisis has been developed by a team of scientists at Massachusetts General Hospital (MGH).
In a study in the journal PNAS, researchers report that the model, known as SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects), presents the most detailed model to date of the crisis by capturing how the interconnections between stages of prescription and illicit opioid use, from initiation and addiction treatment to relapse and overdose mortality, have evolved over time.
"The opioid crisis is so complex that it demands a dynamic simulation tool that can generate reliable data and a big picture perspective on this major public health challenge,” says senior author Mohammad Jalali, PhD, with the MGH Institute for Technology Assessment. "SOURCE provides a dynamic understanding of the trajectory of the opioid crisis that can serve as a framework for projecting future scenarios and informing public policy planning."
Opioid overdose has been responsible for over half a million deaths in the U.S. over the past 21 years. Opioid deaths have grown sharply since 2013, claiming nearly 70,000 victims in 2020 alone, driven in large part by the illicit spread of fentanyl, a powerful opioid that is often mixed with heroin to lethal effect.
Millions of people suffer from opioid use disorder, triggering severe health, social, and economic consequences for the country. In 2017, the National Academies of Sciences, Engineering, and Medicine called for development of a quantitative system model to help understand the crisis and guide policy analysis and decision-making. In response, a team of researchers from MGH and the U.S. Food and Drug Administration (FDA) developed SOURCE.
SOURCE uses national data on opioid use from 1999 to 2020 to track stages of use and misuse of opioids, including use initiation, treatment, relapse and death by overdose.
"Unlike other national models of the crisis, SOURCE replicates how the risks of opioid misuse have evolved over time in response to various behavioral and other factors, and how they may change in the future, providing a platform for projecting and analyzing potential policy impacts and solutions," explains co-author Tse Yang Lim, PhD, with Massachusetts Institute of Technology (MIT).
Among the factors driving these changes are social influence – that is, the spread of drug use behaviors through social exposure – and risk perception, whereby fear of the perceived risk of overdose death can discourage initiation of drug use. SOURCE has also quantified the impact of increased distribution of the overdose reversal drug naloxone, as well as the proliferation of the deadly synthetic substance fentanyl, on overdose death rates. Overall, SOURCE projects that deaths from opioid overdose will increase over the next few years before trending downward as opioid use disorder decreases.
Using SOURCE, the researchers are examining potential strategies to address the opioid crisis as part of an ongoing modeling effort, while continuing to refine the model to reflect the still-evolving nature of the crisis.
"Despite the projected decline, opioid deaths over the next 10 years will still exceed half a million people,” emphasizes co-author Erin Stringfellow, PhD, with MGH. "Fentanyl's poisoning of the unregulated drug supply will continue to be a severe problem, which is why leaders across the country need to be working as hard as they can to keep people who use drugs safe."
Jalali is an assistant professor at Harvard Medical School. Tse Yang Lim is a recent PhD graduate from MIT. Stringfellow is a postdoctoral research associate at the MGH Institute for Technology Assessment. Co-authors include Keith Humphreys, professor and section director for Mental Health Policy at Stanford University, as well as several researchers from the FDA.
The study was supported by the U.S. Food and Drug Administration.
About the Massachusetts General HospitalMassachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World
Related News and Articles
- Patient Education
- Jul | 8 | 2022
How to Get Mental Health Care for Your Child
- Press Release
- Jun | 3 | 2022
A new data-driven model could provide a powerful policy planning tool to combat the nation’s opioid crisis
A Mass General-led team of public health modelers and substance use experts has developed a dynamic model based on national data from 1999 to 2020 that tracks the evolution of the opioid crisis for public policy analysis and development.
- Press Release
- May | 25 | 2022
Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
- Press Release
- Mar | 18 | 2022
The hype over medical marijuana for treating health problems may be exaggerated, researchers find.
- Press Release
- Feb | 8 | 2022
A new clinical review provides guidance to physicians and the public about the most effective tobacco cessation treatments.